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Background
While over the counter weight loss products have grown
into one the largest categories of nutritional supple-
ments, most advertising claims for these products are
limited to proven effects of individual ingredients and
generally demonstrated in fit, active college aged males.
Few commercial weight loss products have been prop-
erly examined in finished commercial form and seldom
have been studied in the overweight and obese popula-
tions. The purpose of this study was to investigate the
acute metabolic effects of the commercial weight loss/
energy product, Fastin-RR® (High-Tech Pharmaceuti-
cals, Inc., Norcross, GA) in overweight and obese men
and women.
Methods
Eleven men (n=6) and women (n=5), 28.5 ± 5 years of
age with BMI between 25 and 35, voluntarily participated
in this research study. All research participants com-
pleted three 6-hour resting metabolic testing sessions in
which three treatment conditions were examined in ran-
domized order including Fastin-RRR (FAS), 300 mg caf-
feine anhydrous (CAF), and cellulose placebo condition
(PL). Metabolic activity was determined in 15 minute
intervals at baseline and 45 minutes, 1½ hr, 3hrs, 4½ hrs
and 6 hrs following ingestion. Metabolic activity was
determined with open flow spirometry (VO2000, Med-
graphics, St. Paul, MN) with outcomes including oxygen
consumption (VO2), respiratory exchange ratio (RER),
minute ventilation (VE) and oxygen extraction (VO2/VE).
Values of metabolic variables were adjusted into change
scores relative to baseline levels. Statistical analyses were
conducted using a 3x6 ANOVA (condition X time) for
repeated measures with the accepted level of significance
set at p<0.05.
Results
Analyses revealed no significant differences between
conditions at baseline in values of VO2, VE, or RER.
Results indicated that VO2 change scores for FAS were
significantly greater at all time points following ingestion
(+22.1%, +18.9%, +15.9%, +12.6%, +8.4%) compared with
PL (0.4%, -1.7%, -2.3%, -1.1%, 0.5%) and compared with
CAF ( +6.3%, +6.5%, +7.1%, +4.2 %, +3.6%) (p’s < 0.05).
Similar response patterns were observed for VE as VO2
with FAS: (+26.6, +22.9%, +23.3%, +18.7%, +9.0%), CAF
(+6.3%, +9.4%, +7.8%, +7.6%, +9.3%) and PL (-1.3%,
-2.5%, -1.9%, -3.6%, +3.1%). The FAS VE change scores
were significantly greater than CAF and PL at 45 min,
90min and 3 hrs (p<0.05). The RER change scores with
PL and CAF were within 2% of baseline values across
the six hours of testing. In contrast, FAS produced a
pattern of declining values of RER over time to 9% and
11% below baseline at 4½ hrs and 6 hrs post ingestion,
respectively, which were significantly less than CAF
and PL.
Conclusion
These findings indicate that resting energy expenditure
is significantly enhanced with Fastin-RR®.
There was approximately 16.6% increase in resting
energy expenditure over the first three hours of testing
with an increase of over 14.5% in energy uptake over
the entire six hour period. These findings also indicate
that Fastin-RR® produced a substantial shift in energy
substrate utilization with significantly greater levels of
fat oxidation.
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